← All trials
NCT05263219
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 10, 2022
- Primary completion
- Feb 9, 2026
- Completion date
- Feb 9, 2026
- First posted
- Mar 2, 2022
- Last posted
- Mar 2, 2022
- Enrollment
- 230
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangzhou Medical UniversityLead sponsor
- First People's Hospital of FoshanCollaborator
- Guangzhou Medical UniversityStudy chair
- Hainan People's HospitalCollaborator
- Jiangmen Central HospitalCollaborator
- Xiamen UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Guangdong Medical UniversityCollaborator
- Maoming People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.